Resinno Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
- Paid Up Capital ₹ 1.08 Cr
- Company Age 7 Year, 20 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 57.25%
- Profit Growth 116.76%
- Ebitda 91.48%
- Net Worth 10.20%
- Total Assets 4.75%
About Resinno Biotech
Resinno Biotech Private Limited (RBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 25 January 2018 (Seven years 20 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vyankatesh Pidiyar and Kafil Ahmed serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85320MH2018PTC304666
-
Company No.
304666
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Jan 2018
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Resinno Biotech Private Limited offer?
Resinno Biotech Private Limited offers a wide range of products and services, including Popular Category, Stomach Care.
Who are the key members and board of directors at Resinno Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kafil Ahmed
|
Managing Director | 25-Jan-2018 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Vyankatesh Pidiyar
|
Director | 28-Apr-2023 | Current |
Financial Performance of Resinno Biotech.
Resinno Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 57.25% increase. The company also saw a substantial improvement in profitability, with a 116.76% increase in profit. The company's net worth Soared by an impressive increase of 10.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Resinno Biotech?
In 2020, Resinno Biotech had a promoter holding of 24.00% and a public holding of 76.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Resinno Biotech?
Unlock and access historical data on people associated with Resinno Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Resinno Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Resinno Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
